PMID: 10095796Mar 30, 1999

Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension. Swedish Quinapril Group

Journal of Internal Medicine
J OstmanH Lithell


To compare the long-term effects of the angiotensin-converting enzyme (ACE)-inhibitor quinapril and the cardioselective beta-adrenergic blocking agent metoprolol on glycaemic control, with glycosylated haemoglobin (HbA1c) as the principal variable, in non-insulin-dependent diabetes mellitus (NIDDM) patients with hypertension. A randomized, double-blind, double-dummy, multicentre study during 6 months preceded by a 4 week wash-out and a 3 week run-in placebo period. Quinapril (20 mg) and metoprolol (100 mg, conventional tablets) were given once daily. No change was made in the treatment of diabetes (diet and hypoglycaemic agents). Seventy-two patients fulfilling the criteria were randomized and entered the double-blind period. Twelve patients did not complete the study. Sixty patients, 26 on quinapril and 34 on metoprolol, were available for the final analysis. The effect was assessed by changes in HbA1c, the fasting serum glucose and the post-load serum glucose, C-peptide and insulin levels during the oral glucose tolerance test. In the quinapril group, the fasting serum glucose, oral glucose tolerance and the C-peptide and insulin responses, determined as the incremental area under the curves (AUC), showed no change, but the m...Continue Reading


Jan 20, 1979·British Medical Journal·A D WrightP H Poole
May 11, 1979·JAMA : the Journal of the American Medical Association·W B Kannel, D L McGee
Mar 1, 1975·Scandinavian Journal of Work, Environment & Health·F GamberaleM Hultengren
Apr 27, 1992·The American Journal of Medicine·B JandrainK V Voorde
Jun 1, 1991·Diabetes Care·P P Stein, H R Black
Oct 1, 1991·European Journal of Clinical Investigation·R O GansA J Donker
Jan 1, 1991·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·H H CrosswellH H Hunt
Jun 1, 1991·Journal of Internal Medicine·P T SawickiM Berger
Dec 1, 1989·Diabetic Medicine : a Journal of the British Diabetic Association·S CapewellA L Muir
Mar 1, 1987·Diabetic Medicine : a Journal of the British Diabetic Association·J S CorcoranJ S Yudkin
Oct 1, 1987·European Journal of Clinical Investigation·K W JauchG Dietze
Jun 26, 1986·The New England Journal of Medicine·S H CroogG H Williams
Apr 1, 1987·Diabetes/metabolism Reviews·K PyöräläM Uusitupa
Jan 1, 1985·Annals of Internal Medicine·M FerriereJ Mirouze
Jan 1, 1985·Annals of Internal Medicine·A M Nadel
Feb 1, 1984·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·P MicossiP Beggi
May 1, 1993·Diabetes Care·S M Haffner
Nov 1, 1995·Clinical and Experimental Hypertension : CHE·M SuzukiY Harano
Jan 1, 1997·Journal of Hypertension·P Palatini, S Julius


Jul 20, 2007·Fundamental & Clinical Pharmacology·Anna Kearney-SchwartzFaiez Zannad
Jan 28, 2010·The American Journal of Cardiology·Jeffrey S Borer, Jean-Claude Tardif
Sep 25, 2018·The Cochrane Database of Systematic Reviews·Clement LoSophia Zoungas
Sep 3, 2010·The British Journal of Nutrition·Catherine E HugginsCaryl A Nowson

Related Concepts

Quinapril hydrochloride
Adrenergic beta-Antagonists
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Blood Glucose
Diastolic Blood Pressure
Diabetes Mellitus, Non-Insulin-Dependent
Double-Blind Method

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.